Search
forLearn
5 / 801 resultslearn isoleucine
learn EUK 134
learn APISCALP™
learn eucalyptus
Research
5 / 1000+ results
research Recent European legal developments on second medical uses and dosage regimes
European patent law now allows patents for new uses and dosages of known drugs, but protection scope is unclear.
research Enzyme‐Instructed Self‐Assembly for Cellular Supramolecular Chemistry
EISA uses enzymes to create precise nanostructures in cells, offering new ways to design adaptive materials and therapies.
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research Biotin deficiency in an infant fed with amino acid formula and hypoallergenic rice
Biotin should be added to Japanese amino acid formula to prevent deficiency.
research Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial.
Rosemary oil and minoxidil 2% both effectively increase hair count in people with androgenetic alopecia, but rosemary oil causes less scalp itching.
Community Join
5 / 1000+ resultscommunity EMAs Response to my Mail i sent them explaining the importance of Finasteride for hairloss in EU
The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.
community Whatever happened at that Japanese conference for Tsuji and Shiseido this weekend?
The conversation discusses the lack of promising results from the 23rd Annual Meeting of Japan Society of Clinical Hair Restoration, with no significant advancements expected in the next five years. Treatments mentioned include setipiprant, with skepticism about its effectiveness.
community IGE Hair Loss and Miniaturization
A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.
community ET-02 Now Recruiting in Texas for Phase 1
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
community ICYMI: Eirion ET-02’s Successful Phase 1 Trial Results for Androgenic Alopecia Treatment
ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.